Medtronic Receives CE Mark Approval for SenSight™ Directional Lead System for DBS Therapy globalbankingandfinance.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globalbankingandfinance.com Daily Mail and Mail on Sunday newspapers.
Study Highlights Potential Clinical Value of ePlex® Blood Culture ID Panels
Major teaching hospital in Grenoble, France demonstrates that ePlex BCID results could have modified antimicrobial treatment in 45% of patients
CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in
Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Identification (BCID) Panels. The study, “Evaluation of Microbiological Performance and the Potential Clinical Impact of the ePlex
® Blood Culture Identification Panels for the Rapid Diagnosis of Bacteremia and Fungemia,” looked prospectively at the identification of pathogens and antimicrobial resistance genes, as well as retrospectively analyzing clinical outcomes, based on ePlex BCID Panel
GenMark Diagnostics, Inc : Study Highlights Potential Clinical Value of ePlex Blood Culture ID Panels finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Jan 28, 2021
WEDNESDAY, Jan. 27, 2021 (HealthDay News) The number of adverse drug reactions (ADRs) associated with hydroxychloroquine and chloroquine more than doubled in 2020 compared with 2018 and 2019, according to a research letter published online Jan. 26 in the
Annals of Internal Medicine.
Justine Perez, Pharm.D., from the Grenoble Alpes University Hospital in France, and colleagues quantified the change in number and type of reported ADRs associated with hydroxychloroquine and chloroquine since the beginning of the COVID-19 pandemic compared to 2018 and 2019.
A total of 21,305 reports of 152,201 suspected ADRs concerning chloroquine and hydroxychloroquine were extracted from the U.S. Food and Drug Administration Adverse Event Reporting System database from Jan. 1, 2018, to Sept. 30, 2020. The researchers found that in 2020, the number of reported ADRs for chloroquine and hydroxychloroquine more than doubled (11,493 and 89,607, respectively) compared with the same months
The American College of Physicians (ACP) and
Annals of Internal Medicine hosted a third virtual COVID-19 vaccine forum on COVID-19 with the focus on the allocation and distribution of available vaccines, a topic that has created controversy as the nation works to get millions of Americans vaccinated.
The forum, Allocation and Distribution: What Physicians Need to Know, was the third in a series of vaccine forums hosted by ACP and
Annals of Internal Medicine and was held on Jan. 22. ACP and
Annals of Internal Medicine invited four experts to offer their perspectives on vaccine allocation and distribution. Panelists included Capt. Amanda Cohn, Chief Medical Officer of the National Center for Immunizations and Respiratory Diseases (NCIRD) and Executive Secretary of the Advisory Committee on Immunization Practices; David Fairchild, MD, MPH, Chief Medical Officer, CVS MinuteClinic, Professor of Medicine, University of Massachusetts Medical School; Wayne J. Riley, MD, MPH, MBA, MAC